Rabeprazole sodium DR is a Small Molecule owned by Eisai, and is involved in 41 clinical trials, which were completed.

Rabeprazole is a selective and irreversible proton pump inhibitor with antisecretory property. Rabeprazole enters the parietal cell and accumulates in the acidic secretory canaliculi where the agent is activated by a proton-catalyzed process that results in the formation of a thiophilic sulfonamide or sulfenic acid. The activated rabeprazole forms covalent bonds with the sulfhydryl amino acids cysteine on the extracellular domain of the proton pump (H+/K+ ATPase) at the secretory surface, thereby inhibiting the transport of hydrogen ions, via exchange with potassium ions, into the gastric lumen.

The revenue for Rabeprazole sodium DR is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rabeprazole sodium DR NPV Report.

Rabeprazole sodium DR is originated and owned by Eisai.

Rabeprazole sodium DR Overview

Rabeprazole Sodium (Aciphex, Pariet, parit) is a substituted benzimidazole. It is formulated as delayed-release tablets, film coated tablets, coated tablets and hard gelatin capsules for oral administration. It is indicated for short-term treatment (around 4 to 8 weeks treatment) in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD), for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease, for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults and adolescents 12 years of age and above. It is also indicated for the short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers and for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. Other than US, the drug is known by the trade name “Pariet”. Rabeprazole sodium also received approval as an additional indication in Japan for gastritis by triple therapy. The drug candidate received approval in United States for pediatric formulation Aciphex Sprinkle Delayed-Release Capsules. Pariet is used in the prevention of recurrent gastric or duodenal ulcers caused by low-dose aspirin therapy. Pariet is under development for maintenance therapy for proton pump inhibitor (PPI)-resistant reflux esophagitisfunctional (non ulcer) in Japan. It was also under development for dyspepsia in Japan.

Eisai Overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY756,226 million for the fiscal year ended March 2022 (FY2022), an increase of 17.1% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 8% in FY2021. In FY2022, the company recorded a net margin of 6.3%, compared to a net margin of 6.5% in FY2021. The company reported revenues of JPY174,364 million for the second quarter ended September 2022, a decrease of 5.4% over the previous quarter.

Quick View – Rabeprazole sodium DR

Report Segments
  • Innovator (NME)
Drug Name
  • Rabeprazole sodium DR
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.